Market comparison

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)

1 venue · 1 outcome rows · 0 comparable lines · 0 verified parity · resolved

Kalshi

1 outcomes · $5K reported volume

Observed 537h ago · stale

Recorded venue end date: Jan 1, 2027

Check settlement rules before comparing contracts. Matched outcomes may settle differently. These are stored prices; record update times do not certify live quotes. Differences exclude fees and available size.

No shared outcome identities or comparable outcome lines are available for this event. Each venue’s outcomes are listed separately.

Available outcome prices by venue for FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
Outcome	Kalshi	Difference
a full approval or an accelerated approval Not aligned No persisted outcome identity connects these venue contracts.	1.0%stale Bid and ask hidden: prices are over 2 hours old a full approval or an accelerated approval · closed Open Kalshi ↗	—

a full approval or an accelerated approval

Not aligned

No persisted outcome identity connects these venue contracts.

Kalshi

1.0%stale

Bid and ask hidden: prices are over 2 hours old

a full approval or an accelerated approval · closed

Open Kalshi ↗

Prices are shown as percentages of a $1 payout. “pp” means percentage points. A dash means data is unavailable.

View event details, charts and rules →Explore more markets